Phase
Condition
Coronary Artery Disease
Atherosclerosis
Vascular Diseases
Treatment
Placebo
Vitamin K
Clinical Study ID
Ages > 60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Men and women
Age 60 years and older
Medically documented stable Coronary Heart Disease (CHD)
Daily dietary intakes of phylloquinone <150 mcg
Non-consumption of vitamin K supplements (i.e. K1 or K2, singly or in combinationwith other nutrients), or other cognitive aids
Good French or English understanding
Physical exercise not exceeding 2.5 hours/week of moderate to vigorous aerobicactivity
Capacity and willingness to sign informed consent
Exclusion
Exclusion Criteria:
Recent acute coronary syndrome (<3 months) or recent coronary revascularization (bypass surgery or percutaneous coronary intervention, <3 months)
Known left ventricular dysfunction (LVEF < 40%) or chronic heart failure
Recent modification of medication (<2 weeks)
Warfarin (Coumadin) use
Cognitive impairment (based on telephone version of the Mini-Mental StateExamination test, score <19/23)
Diagnosis of depression or uncontrolled anxiety
Malabsorption disorder (advanced liver disease, Crohn's disease)
Patient with auditory or vision impairments not properly corrected by glasses orhearing aids
Unable to read the informed consent form or unable to understand the oralexplanations provided by the assessor
Study Design
Study Description
Connect with a study center
Montreal Heart Institute
Montreal, Quebec H1T 1C8
CanadaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.